Immune checkpoint inhibitors (ICI) myopathy

Evidence-based neurology checklist on immune checkpoint inhibitors (ici) myopathy: Causes Nivolumab Pembrolizumab Ipilimumab Durvalumab Atezolizumab Onset features Clinical features Overlap features Differential diagnosis Investigations Prognosis Treatment

Causes

  • Nivolumab
  • Pembrolizumab
  • Ipilimumab
  • Durvalumab
  • Atezolizumab

Onset features

Clinical features

Overlap features

Differential diagnosis

Investigations

Prognosis

Treatment

References

  1. Touat M, Maisonobe T, Knauss S, et al. Immune checkpoint inhibitor-related myositis and myocarditis in patients with cancer. Neurology 2018; 91:e985-e994.
  2. Shah M, Tayar JH, Abdel-Wahab N, Suarez-Almazor ME. Myositis as an adverse event of immune checkpoint blockade for cancer therapy. Semin Arthritis Rheum 2019; 48:736-740.
  3. Beecher G, Pinal-Fernandez I, Mammen AL, Liewluck T. Immune checkpoint inhibitor myopathy: the double-edged sword of cancer immunotherapy. Neurology 2024; 103:e210031.
  4. Moreira A, Loquai C, Pföhler C, et al. Myositis and neuromuscular side-effects induced by immune checkpoint inhibitors. Eur J Cancer 2019; 106:12-23.
  5. Uchio N, Taira K, Ikenaga C, et al. Inflammatory myopathy with myasthenia gravis: thymoma association and polymyositis pathology. Neurol Neuroimmunol Neuroinflamm 2018; 6:e535.
  6. And 1 more. Subscribe to see the full list

Related checklists

Loading...